Login
← Go Back
Cohance Lifesciences
COHANCE · Pharma > Pharmaceuticals & Drugs · Chairman: Venkateswarlu Jasti · MD: Venkateswarlu Jasti · Listing date: March 10, 2020 · Employees: 1114 · Hyderabad · http://www.suvenpharm.com
Stock Price vs Company Growth
1d
1.8%
1w
14.2%
1m
20.7%
3m
14.7%
6m
59.6%
1y
69.7%
5y
5.0%
all
13.9%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 363 1.8%
268
428
Company Overview
Sales
2,051 Cr
Growth: 17.7%
Profit after Tax
202 Cr
Growth: -36.6%
Mid Cap
13,897 Cr
P/E: 63.2x
Industry P/E: 28.0x
Fundamentals
Sales (Cr) ₹ 2,051
Growth 17.7%
EBITDA 19.6%
P/S 6.8x
Dividend 0.0%
P/E 63.2x
Book Value ₹ 48.9
PEG Ratio 3.5x
ROE 11.3%
P/B 7.4x
Shareholding Pattern
Institutions
Uti Small Cap Fund
2.17 %
L And T Mutual Fund Trustee Ltd-L And T Mid Cap Fund
1.95 %
Promoters
Jasti Property And Equity Holdings Private Limited(Initscapacityassoletrusteeofjastifamilytrust)
60.0 %
Others
Rambabu Chirumamilla
2.14 %
Qualified Institutional Buyer
0.7 %
Iepf
0.14 %
Increase    Decrease    No change
Company Profile Detailed
The company is a fully integrated global CDMO, partnering with leading innovators across the entire product lifecycle- from route scouting and early development to commercial manufacturing. With advanced capabilities in oligonucleotides, bioconjugation and complex small molecules, it addresses some of the most challenging chemistries in the industry.
Belongs to (29 Indices) view more
Investors (34)
landt.mu...
sbi.mutu...
marshall...
Followers (4)
ramakris...
krishna5...
venkatja...